Artificial intelligence-driven specific gut microbiome as a predictive biomarker for the therapeutic response to cancer immunotherapy in lung cancer- a multicenter prospective observational study-

Artificial intelligence-driven specific gut microbiome as a predictive biomarker for the therapeutic response to cancer immunotherapy in lung cancer- a multicenter prospective observational study- - Artificial intelligence-driven specific gut microbiome as a predictive biomarker for the therapeutic response to cancer immunotherapy in lung cancer- a multicenter prospective observational study-

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000046428

Enrollment

400

Registered

2021-12-21

Start date

2021-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced/recurrent lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) pathologically or cytologically confirmed non-small cell lung cancer or small cell lung cancer (2) Planned to treat with cancer immunotherapy (3) Informed consent obtained from patients

Exclusion criteria

Exclusion criteria: (1) Patients have already received cancer immunotherapy (2)Inadequate cases judged by doctors

Design outcomes

Primary

Measure	Time frame
To establish the predictive system of therapeutic response to cancer immunotherapy using gut microbiome in lung cancer	—

Countries

Japan

Contacts

Public ContactFumihiro Shoji

National Hospital Organization Kyushu Cancer Center Department of Thoracic Oncology

fshoji@surg2.med.kyushu-u.ac.jp09054881926

Outcome results